NCT lookup

Inclusion Criteria:

* Probable Alzheimer's Disease (AD) dementia or prodromal AD.
* Availability of a reliable study partner (non-professional caregiver) who accepts to participate in study procedure throughout the study duration
* The participant should be capable of completing all aspects of study assessments including MRI, clinical genotyping, and PET imaging, either alone or with the help of the study partner (non-professional caregiver).
* Adequate visual and auditory acuitysufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted).
* Evidence of AD pathological process, as confirmed by amyloid PET scan by qualitative read by the core/central PET laboratory.
* Prodromal or mild symptomatology, as defined by a screening Mini-Mental State Examination (MMSE) score \>/=22 and Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1.0, as well as a clinical dementia rating (CDR) memory domain score \>/=0.5.
* If the participant is receiving symptomatic AD medications, a stable dosing regimen for at least 3 months prior to screening and until start of study treatment.
* Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug.
* Agreement not to participate in other research studies for the duration of this trial, unless these are related Roche-sponsored non-interventional studies.
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods hat result in a failure rate of \< 1% per year during the treatment period and for at least 16 weeks after the final dose of study drug.

Exclusion Criteria:

* Any evidence of a condition other than AD that may affect cognition.
* History or presence of clinically evident systemic vascular disease that in the opinion of the investigator has the potential to affect cognitive function.
* History or presence of clinically evident cerebrovascular disease.
* History or presence of posterior reversible encephalopathy syndrome.
* History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack.
* History of severe, clinically significant CNS trauma.
* History or presence of intracranial mass that could potentially impair cognition.
* Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae.
* History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits.
* History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder.
* At risk for suicide in the opinion of the investigator.
* Alcohol and/or substance abuse or dependants in past 2 years.

• Atlantis, Florida, United States
• Maitland, Florida, United States
• Ocala, Florida, United States
• Wellington, Florida, United States
• Gainesville, Georgia, United States
• Portland, Oregon, United States
• Willow Grove, Pennsylvania, United States
• Hasselt, Belgium
• Kortrijk, Belgium
• Leuven, Belgium
• Bron, France
• Paris, France
• Toulouse, France
• Berlin, Germany
• Berlin, Germany
• München, Germany
• Tricase (LE), Apulia, Italy
• Rome, Lazio, Italy
• Milan, Lombardy, Italy
• Bydgoszcz, Poland
• Lublin, Poland
• Sopot, Poland
• Szczecin, Poland
• Warsaw, Poland
• Wroc?aw, Poland
• Donostia / San Sebastian, Guipuzcoa, Spain
• Pozuelo de Alarcón, Madrid, Spain
• Madrid, Spain
• Madrid, Spain
• Valencia, Spain
• + 4 more on CT.gov